Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...
Onlymyhealth17h
India Approves Living Drug To Treat Blood Cancer: All About Qartemi And How It Works
India introduces Qartemi a groundbreaking CAR-T cell therapy to fight advanced blood cancers like B-cell Non-Hodgkin Lymphoma ...
India approves 'living drug' Qartermi to treat blood cancer; here's what you need to know
Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...